People carrying this genetic variant had, on average, lower systolic and diastolic blood pressure and an approximately 14% ...

The majority of patients with type 2 diabetes (T2D) have less than ideal metabolic control despite our greater understanding of the underlying pathophysiologic mechanisms of hyperglycemia and the ...

A landmark clinical trial showed that nearly half of participants achieved remission from type 2 diabetes. The results are changing how doctors think about the disease.

Health-related quality of life (HRQoL) in type 2 diabetes encompasses the physical, psychological and social dimensions of well-being as experienced by individuals living with the condition. Beyond ...

Type 2 diabetes represents a growing global health burden, with early detection and risk stratification pivotal to reducing complications and healthcare costs. Screening programmes employ a range of ...

This review describes how gut microbial messengers, including SCFAs, microbiota-modified bile acids, neuroactive metabolites, ...

The data revealed that between 2017 and 2024, the number of young women under 40 diagnosed with type-2 diabetes jumped by 47% ...

According to the review, beneficial gut bacteria produce compounds such as short-chain fatty acids (SCFAs) that help regulate ...

In a recent review published in the journal Diabetes Care, Daniel J. Drucker of Lunenfeld-Tanenbaum Research Institute, University of Toronto, evaluated the efficacy and safety of glucagon-like ...

Lifestyle changes such as eating a diabetes-friendly diet, exercising more, and maintaining a healthy body weight combined with existing treatment options are the best way to prevent or manage type 2 ...

CGM technology is becoming increasingly advanced, Dr Ashrafi said. He added: “Many devices now offer phone connectivity, ...

Medicines called glucagon-like peptide-1 (GLP-1) receptor agonists have changed how type 2 diabetes is treated. GLP-1 medicines, like Rybelsus (semaglutide), work by acting like the body’s natural GLP ...